SCHEMBL5539616

SCHEMBL5539616

CCOc1ccc(CN2CC[N]C2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.53
GRM2 Q14416 1/20 0.49
KDM4E B2RXH2 5/20 0.46
TDP1 Q9NUW8 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.42
TP53 P04637 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NQO1 P15559 1/20 0.41
FAAH O00519 1/20 0.41
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540360 0.89 TSHR (0.54) MEN1KMT2AL3MBTL1TP53ALDH1A1
SCHEMBL5546843 0.86 RAB9A (0.54) MEN1KMT2ATP53ALDH1A1GAA
SCHEMBL5541487 0.85 NPC1 (0.56) MEN1KMT2ATP53GAAHPGD
SCHEMBL5536668 0.85 GAA (0.55) GRM2KDM4EMEN1KMT2APOLB
SCHEMBL5536814 0.81 P2RX3 (0.46) GRM2MEN1KMT2APOLBLMNA
SCHEMBL5543146 0.78 ERCC1 (0.46) GRM2KDM4ELMNASMN1; SMN2ALDH1A1
SCHEMBL9705989 0.77 GAA (0.52) GRM2MEN1KMT2APOLBSMN1; SMN2
SCHEMBL9704138 0.76 ERCC1 (0.39)
SCHEMBL5539260 0.76 ALDH1A1 (0.56) GRM2MEN1KMT2APOLBLMNA
SCHEMBL5540694 0.76 ALDH1A1 (0.42) GRM2KDM4EMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ACACB 1653/4885GRM2 248/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.